PPT-PrEP Considerations for HPX3002/HVTN 706

PrEP Considerations for HPX3002HVTN 706 Susan Buchbinder HVTN Study ChairSan Francisco Site PI PrEP is safe and highly effective against sexual exposures for MSM and TGW 4 DosesWeek has Similar Efficacy to Daily TDFFTC for MSM. Step 3: Summary Findings. APRIL. 2016. This toolkit is designed to help implementers plan for introduction and roll out of oral . PrEP.. The toolkit enables implementers to 1) catalogue the current situation at the country-level for the introduction of Oral PrEP, 2) identify existing assets and strengths that could be leveraged for PrEP introduction, and 3) highlight gaps in understanding, processes, or resources that will need to be addressed to support successful PrEP introduction. By working through these three steps, implementers will complete a Situation Analysis that can be used to guide planning and preparation for the launch and scale-up of oral . Module . 1(b). The Evidence in Detail. Session Overview. Seroconversion rates. PrEP. Studies: MSM, transgender population, women, discordant couples. Benefits of . PrEP. Barriers to . PrEP. services. Katherine Marx, MS, MPH, FNP-BC. June 2014. Disclosure. I, Katherine Marx, have no relevant financial, professional, or personal relationships to disclose.. Objectives. Know current US recommendations for . Online ACT Prep Overview Method Test Prep (MTP) What is Method Test Prep? Free, online ACT prep program Available to all South Dakota high school students with the exception of home school students Consists of lessons, quizzes, evaluation tests, vocabulary practice, full length exams divided by subtest Pre-Exposure Prophylaxis ( PrEP ) for HIV Infection Jeffrey D. Klausner, MD, MPH Professor of Medicine and Public Health University of California Los Angeles Attending Physician UCLA Center AIDS Research and Education and Ronald Reagan Medical Center P r EP introduction for Adolescent Girls and Young Women Girls and HIV AIDS2016 Satellite Session Durban, South Africa July 21, 2016 Sanyukta Mathur, Population Council What is Oral PrEP ? New biomedical tool to prevent HIV infection 2015’s Top Ten List for the HIV Prevention Research Field. Manju Chatani, Stacey Hannah, Mitchell Warren. Thursday, January 29. th. , 2015. What to watch in . PrEP. . research in 2015…. Launch of two Phase II Long-Acting Injectable ARV Trials . PrEP. Products. IAS 2016. MTN Symposium . Nelly . Rwamba. Mugo . Kenya Medical Research Institute (KEMRI). University of Washington-ICRC, Department of Global Health. Partners in Health . R. esearch and Development (PHRD)-. Community Engagement in HIV Prevention Efficacy Trials: The AMP Studies’ Experience . (HVTN 704/HPTN 085 & HVTN 703/HPTN 081) . Michele Andrasik, PhD. Director, Social & Behavioral Sciences and Community Engagement. HVTN 702 Protocol Team. Confidential – Do Not Distribute. 3 Novel Strategies for Efficacy. P5 . strategy based on the Thai . Trial . (RV144) Primary Results. 0.0. 0.5. 1.0. 1.5. 2.0. 2.5. 3.0. 3.5. Manju Chatani, Stacey Hannah, Mitchell Warren. Thursday, January 29. th. , 2015. What to watch in . PrEP. research in 2015…. Launch of two Phase II Long-Acting Injectable ARV Trials . Data from IPERGAY and PROUD PrEP Trials. Kimberly Green. Director, Primary Health Care. PATH. kgreen@path.org. More than . 1.3 million . people took PrEP at least once by June 2021. Source: Jessica Rodrigues, AVAC, IAS2021. PrEP use has accelerated but is still far from meeting . Nono Mkhize, PhD. National Institute for Communicable Diseases, a division of the . National Health Laboratory Service . (NHLS) of . South Africa, . . University of the Witwatersrand, Johannesburg, South . Welcome to the era of PrEP choice. Rose Nyirenda, Ministry of Health, Malawi. Declining HIV incidence: 0.1% (15-49 years). Generalized epidemic: distribution of 14,000 new infections. 70% in general population (excl. AGYW).